Condensed Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues:
Revenues	$ 6,577	$ 5,604	$ 17,268	$ 16,570
Costs and expenses:
Cost of goods sold	1,141	1,035	3,174	2,992
Research and development expenses	1,158	1,030	3,461	2,956
Acquired in-process research and development expenses	1,171	3,960	5,792	4,251
Selling, general and administrative expenses	1,106	1,052	3,421	3,177
Total costs and expenses	4,576	7,077	15,848	13,376
Income (loss) from operations	2,001	(1,473)	1,420	3,194
Interest expense	(236)	(250)	(717)	(752)
Other income (expense), net	(940)	222	(848)	817
Income (loss) before income taxes	825	(1,501)	(145)	3,259
Income tax expense (benefit)	472	(333)	1,310	584
Net income (loss)	353	(1,168)	(1,455)	2,675
Net loss attributable to noncontrolling interest	(7)	(3)	(27)	(15)
Net income (loss) attributable to Gilead	$ 360	$ (1,165)	$ (1,428)	$ 2,690
Net income (loss) per share attributable to Gilead common stockholders - basic (usd per share)	$ 0.29	$ (0.92)	$ (1.14)	$ 2.12
Shares used in per share calculation - basic (in shares)	1,255	1,267	1,257	1,271
Net income (loss) per share attributable to Gilead common stockholders - diluted (usd per share)	$ 0.29	$ (0.92)	$ (1.14)	$ 2.10
Shares used in per share calculation - diluted (in shares)	1,261	1,267	1,257	1,278
Product sales
Revenues:
Revenues	$ 6,493	$ 5,516	$ 17,027	$ 16,323
Royalty, contract and other revenues
Revenues:
Revenues	$ 84	$ 88	$ 241	$ 247